The yielded prodrug, combined with the STING agonist MSA‐2, was assembled with cyclodextrin‐grafted hyaluronic acid (HA‐CD) to form a supramolecular prodrug nanovector, designated HCCSM, with an average diameter of appropriately ≈104.3 nm.[51] Intravenous administration of HCCSM nanovectors in a subcutaneous CT26 colorectal tumor model significantly delayed the tumor progression of both primary and distant tumors compared to controls treated with a soluble formulation of CPT+MSA‐2 or CCSM nanovectors lacking HA modification. This evidence concerns the gene STING1 and neoplasm.